Publications: MRSA (Methicillin-resistant Staphylococcus aureus)

For updated information on the MRSA surveillance program, please visit CDC’s Healthcare-associated Infections – Community Interface webpage.

2005 to Present (9-site surveillance):

• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2014.
• Johnson NB, Hayes LD, Hoo EC, Ethier KA. CDC national health report: Leading causes of morbidity and mortality and associated risk and protective factors – United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014;63(04):3-27.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2013.
• Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970-8.
• Duffy J, Dumyati G, Bulens S, et al. Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge. Am J Infect Control. 2013;41(9):782-6.
• Iwamoto M, Mu Y, Lynfield R, et al. Trends in invasive methicillin-resistant Staphylococcus aureus Pediatrics. 2013;132(40):e817-24.
• Nguyen DB, Lessa FC, Belflower R, et al. Invasive methicillin-resistant Staphylococcus aureus infections among chronic dialysis patients in the United States, 2005-2011. Clin Infect Dis. 2013;57:1393-400.
• Tosh PK, Bulens SN, Nadle J, et al. Characterization of hospitalized community-onset Staphylococcus aureus lower respiratory tract infections among generally healthy persons 50 years of age or younger. Infect Dis Clin Prac. 2013;21:359-65.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2012.
• Bender JB, Waters KC, Nerby J, Olsen KE, Jawahir S. Methicillin-resistant Staphylococcus aureus (MRSA) isolated from pets living in households with MRSA-infected children. Clin Infect Dis. 2012;54(3):449-50.
• Hadler JL, Petit S, Mandour M, Cartter ML. Trends in invasive infection with methicillin-resistant Staphylococcus aureus, Connecticut, 2001-2010. Emerg Infect Dis. 2012; 18(6):917-924.
• Lessa FC, Mu Y, Ray SM, et al. Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin Infect Dis. 2012;55(2):232-41.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2011[3 pages].
• DeVries A, Lesher L, Schlievert PM, et al. Staphylococcal toxic shock syndrome 2000-2006: Epidemiology, clinical features, and molecular characteristics. PLoS One. 2011:6(8):e22997.
• Nerby JM, Gorwitz R, Lesher L, et al. Risk factors for household transmission of community-associated methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2011;30(11):927-932.
• Satola SW, Lessa FC, Ray SM, et al. Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: Lack of effect of heteroresistant vancomycin-intermediate aureus phenotype. J Clin Microbiol. 2011;49(4):1583-87.
• Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011;49(1):177-83.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2010[4 pages].
• Como-Sabetti KJ, Harriman KH, Fridkin SK, Jawahir SL, Lynfield R. Risk factors for community-associated Staphylococcus aureus infections: Results from parallel studies including methicillin-resistant and methicillin-sensitive aureus compared to uninfected controls. Epidemiol Infect. 2010;1:1-11.
• Kallen A, Mu Y, Bulens S, et al. Healthcare-associated invasive MRSA infections, 2005-2008. 2010;304(6):641-48.
• Kempker RR, Farley MM, Ladson JL, Satola S, Ray SM. Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia. J Infect. 2010;61:372-81.
• Lessa FC, Mu Y, Davies J, et al. Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006-2007. Clin Infect Dis. 2010;51(8):925-28.
• Shukla SK, Karow ME, Brady JM, et al. Virulence genes and genotypic associations in nasal carriage, community-associated methicillin-susceptible and methicillin-resistant USA400 Staphylococcus aureus J Clin Microbiol. 2010;48(10):3582-92.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2009[3 pages].
• Limbago B, Fosheim GE, Schoonover V, et al. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: A population-based analysis. J Clin Microbiol. 2009;47(5):1344-51.
• Lucero CA, Hageman J, Zell ER, et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through the use of population-based surveillance for invasive methicillin-resistant aureus disease in the United States. Vaccine. 2009;27(37):5061-68.
• Buck JM, Harriman KH, Juni BA, et al. No change in methicillin-resistant Staphylococcus aureus nasal colonization rates among Minnesota school children during 2 study periods. Infect Dis Clin Pract. 2008;16(3):163-5.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2008.
• Tenover FC, McAllister S, Fosheim G, et al. Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J Clin Microbiol. 2008;46(9):2837-41.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2007.
• Klevens MR, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. 2007;298(15):1763-71.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2006.
• Klevens MR, Morrison MA, Fridkin SK, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis. 2006;12:1991-3.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2005.

Early phase ABCs MRSA (4-site surveillance):

• Buck JM, Como-Sabetti K, Harriman KH, et al. Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003. Emerg Infect Dis. 2005;11(10):1532-8.
• Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436-44.
• Naimi TS, LeDell KH, Como-Sabetti K,et al. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus JAMA. 2003;290:2976-84.
• Morin C, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in four metropolitan areas in Connecticut, 1998. J Infect Dis. 2001;184:1029-34.

 Top of Page